Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 5
2005 3
2006 2
2007 2
2008 1
2009 1
2011 3
2012 2
2013 3
2014 3
2015 4
2016 3
2017 2
2018 2
2019 10
2020 14
2021 10
2022 4
2023 9
2024 6
2025 9
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Among authors: domingo domenech e. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
Sehn LH, Hübel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jiménez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M; inMIND Study team. Sehn LH, et al. Among authors: domingo domenech e. Lancet. 2026 Jan 10;407(10524):133-146. doi: 10.1016/S0140-6736(25)01778-7. Epub 2025 Dec 5. Lancet. 2026. PMID: 41360064 Clinical Trial.
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.
Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM. Zinzani PL, et al. Among authors: domenech ed. Lancet Oncol. 2024 Dec;25(12):1602-1613. doi: 10.1016/S1470-2045(24)00503-5. Epub 2024 Oct 29. Lancet Oncol. 2024. PMID: 39486433 Free PMC article. Clinical Trial.
Unraveling the genetics of transformed splenic marginal zone lymphoma.
Grau M, López C, Navarro A, Frigola G, Nadeu F, Clot G, Bastidas-Mora G, Alcoceba M, Baptista MJ, Blanes M, Colomer D, Costa D, Domingo-Domènech E, Enjuanes A, Escoda L, Forcada P, Giné E, Lopez-Guerra M, Ramón O, Rivas-Delgado A, Vicente Folch L, Wotherspoon A, Climent F, Campo E, López-Guillermo A, Matutes E, Beà S. Grau M, et al. Among authors: domingo domenech e. Blood Adv. 2023 Jul 25;7(14):3695-3709. doi: 10.1182/bloodadvances.2022009415. Blood Adv. 2023. PMID: 36995085 Free PMC article.
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Domingo-Domènech E, Pro B, Illidge T, Horwitz S, Trumper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Kim WS, Feldman T, Choi I, Gritti G, Belada D, Shustov A, Illes A, Zinzani PL, Hüttmann A, Trneny M, Le Gouill S, Jagadeesh D, Friedberg JW, Little M, Dong C, Fanale M, Fenton K, Savage KJ. Domingo-Domènech E, et al. Blood Cancer J. 2025 Aug 1;15(1):129. doi: 10.1038/s41408-025-01329-2. Blood Cancer J. 2025. PMID: 40750774 Free PMC article. Clinical Trial.
Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.
Iyer S, Mehta-Shah N, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Alpdogan O, Feldman TA, Camus V, Gritti G, Zinzani PL, Belada D, Mayer J, Choi I, Cheong JW, Rustia E, Fenton K, Fanale M, Savage KJ, Horwitz SM. Iyer S, et al. Among authors: domingo domenech e. Blood Adv. 2025 Dec 9;9(23):5976-5987. doi: 10.1182/bloodadvances.2024015282. Blood Adv. 2025. PMID: 40829107 Free PMC article. Clinical Trial.
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.
Johnson NA, Zinzani PL, Domingo-Domenech E, Brody J, Kline J, Shah BD, Mehta AN, Ghesquieres H, Savage KJ, Barr PM, Santoro A, Ferrari S, Cunningham D, Collins GP, Fanale M, Krajewski J, Akyol A, Crowe R, Wen R, Kuruvilla J. Johnson NA, et al. Among authors: domingo domenech e. Future Oncol. 2026 Jan;22(1):93-99. doi: 10.1080/14796694.2025.2599082. Epub 2025 Dec 10. Future Oncol. 2026. PMID: 41367262 Free PMC article. Clinical Trial.
Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study.
Sureda A, García-Sanz R, Domingo-Domenech E, Capote FJ, Gutiérrez A, Rodriguez A, Aguiar D, Giraldo P, Infante MS, López-Jiménez J, Martínez C, Sánchez-González B, Ortiz-Romero PL, Grande M, Baeza-Montañez L. Sureda A, et al. Among authors: domingo domenech e. Cancers (Basel). 2025 Mar 28;17(7):1137. doi: 10.3390/cancers17071137. Cancers (Basel). 2025. PMID: 40227660 Free PMC article.
91 results